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Background: Migraine is a highly disabling neurovascular primary headache disorder, with 
its exact pathomechanism being still unrevealed. The current leading hypotheses are based on 
the sensitization and activation of the trigeminovascular system. 
Objective: To review the literature with focus on the effects of kynurenines (L-kynurenine 
and kynurenic acid) and pituitary adenylate cyclase-activating polypeptide on the regulation 
of the trigeminovascular system. 
Method: A literature search was conducted to identify preclinical and clinical publications 
(198 references) by using the keywords ‘kynurenines’, ‘pituitary adenylate cyclase-
activating polypeptide’, and ‘migraine’ in the database of MEDLINE/PubMed up to 10 
September 2016for topical review. Additional filters used included ‘review’, ‘systematic 
review’, ‘original article’, and ‘English language’. 
Results: L-kynurenine and kynurenic acid act on the glutamatergic system at the level of the 
second-order nociceptive neurons in the trigeminal nucleus caudalis. Pituitary adenylate 
cyclase-activating polypeptide is released from the peripheral nerve endings of the trigeminal 
pseudounipolar neurons and causes vasodilation and mast cell degranulation, leading to 
consequent peripheral sensitization of the dural nociceptors. Centrally released pituitary 
adenylate cyclase-activating polypeptide in the trigeminal nucleus caudalis results in the 
central sensitization of the second-order neurons. The sensitization process leads to the 
characteristic features of migraine. 
Conclusion: L-kynurenine, kynurenic acid, and pituitary adenylate cyclase-activating 
polypeptide may have fundamental roles in the initiation of migraine headache attacks. 















































































Abbreviations: AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, KYNA: 
kynurenic acid, L-KYN: L-kynurenine, NMDA: N-methyl-D-aspartate, PACAP: pituitary 




Keywords: glutamate, kynurenine, migraine, mode of action, pathomechanism, pituitary 
adenylate cyclase-activating polypeptide. 
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Migraine as a neurovascular primary headache disorder is ranked the third most common 
disease worldwide [1]. On the basis of the latest classification of the International Headache 
Society, migraine can be divided into episodic (with and without aura) and chronic forms [2]. 
The typical features of a migraine attack include the unilateral location, pulsating quality, 
moderate or severe intensity, aggravation by routine physical activity, and association with 
nausea and/or photophobia and phonophobia [2]. Migraine is a disabling disease, having high 
socio-economic and personal impacts [3-9]. 
The exact pathomechanism of migraine is still unrevealed. The proposed pathogeneses of the 
initiation and maintenance of a migraine attack include neuro-vascular alterations, 
neuropeptide release, neurogenic inflammation, plasma protein extravasation, peripheral and 
central sensitization, cortical spreading depression (CSD), brain energy deficit, and lesions in 
the cerebral white matter [10-14]. The trigeminovascular system (TS) provides an important 
pain transmission link between the vascular andneuronal elements [15, 16]. 
The TS includes the primary sensory pseudounipolar neurons, the cell bodies of which are 
located in the trigeminal ganglion (TRIG). Their peripheral branches innervate the cranial 
vessels and meningeal tissues, whereas their central fibers project to the area of the second-
order neurons within the trigeminal nucleus caudalis (TNC) in the brainstem. The information 
is conveyed to the somatosensory cortex via the third-order neurons located in the thalamus 
[13, 14]. 
The coupling mechanism in the TNC is controlled by descending pathways from distinct 
brainstem nuclei, e.g., the periaqueductal grey matter (PAG), the nucleus raphe magnus 
(NRM), the dorsal raphe nucleus (DRN), and the locus coeruleus (LC), collectively referred 
to as the migraine generators [14, 17]. 
It has recently been suggested that glutamate, kynurenines, and pituitary adenylate cyclase-
activating polypeptide (PACAP) may play fundamental roles in the initiation and 
chronification of migraine headache attacks [18, 19]. 
Glutamate plays a pivotal role in neurotransmission, and emerging human and animal data 
suggest that it is crucial in the pathomechanism of migraine. Indeed, elevated levels of 
glutamate were detected in the plasma, platelets, and cerebrospinal fluid in migraine patients 
long after the attacks, supporting the hypothesis of a sustained hyperexcitability in the disease 
[20-22]. It is worthy of note that several genetic polymorphisms that affect glutamatergic 
neurotransmission have been described in migraineurs [23, 24]. It is also important to note 
































































that glutamate receptor antagonists can terminate the aura in patients with familial hemiplegic 
migraine [25]. Monosodium glutamate is a naturally appearing form of glutamic acid and is 
able to mimic headache in healthy young volunteers and in rats, an effect mediated by the 
activation of peripheral N-methyl-D-aspartate (NMDA) receptors and dural vasodilation. Data 
from the literature demonstrate that glutamate has a prominent role in processes important in 
migraine generation, such as CSD and the activation and sensitization of the trigeminal 
system, and it is also present in the migraine generators [26-28]. Taken together, it seems 
clear that the role of glutamate is relevant in the pathomechanism of migraine, and its 
antagonists may have a therapeutic potential. 
Kynurenines are less widely known but highly important products of tryptophan (Trp) 
metabolism [29]. L-kynurenine (L-KYN) and kynurenic acid (KYNA) have neuroprotective 
effects, whereas 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HA), and 
quinolinic acid (QIUN) have neurotoxic properties [18, 29]. KYNA is one of the endogenous 
glutamate receptor antagonists. Preclinical data revealed that L-KYN or synthetic analogues 
of KYNA can dramatically inhibit the activation of second-order neurons in the TNC in 
animal models of migraine with electrically or chemically stimulated TS [30-33]. Furthermore, 
L-KYN and KYNA can block the process of CSD in experimental conditions [34, 35]. In 
recent years, clinical studies have demonstrated multiple alterations in the levels of different 
kynurenine pathway metabolites (e.g., a reduction in the level of L-KYN and an increased 
level of anthranilic acid (ANA)) in the serum of chronic migraine patients [36]. 
PACAP is a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon 
neuropeptide family and exists in two biologically active forms: PACAP1-27 and PACAP1-
38[37]. The presence of PACAP in human TRIG and TNC has been demonstrated [38, 39]. 
The importance of PACAP in migraine has first been pointed out by clinical studies [40]. 
Intravenous administration of PACAP1-38 provoked migraine-like attacks accompanied by 
vasodilation in migraine patients [40, 41]. Experimental data revealed the effect of PACAP on 
the TS in migraine animal models as well [42, 43]. In line with these, alterations in plasma 
PACAP1-38 concentration have been demonstrated in migraineurs both ictally and 
interictally [44]. 
This paper gives an overview of the currently available data as regards the contribution of the 
kynurenine pathway and PACAP in the pathogenesis of migraine, with special focus on 
potential therapeutic implications. 
 
 


































































Chemistry of the kynurenine pathway 
 
Trp is an essential amino acid, playing a crucial role in the synthesis of serotonin, melatonin, 
tryptamine, and L-KYN ((S)-2-amino-4-(2-aminophenyl)-4-oxobutonic acid). The major 
branch of Trp metabolism is the kynurenine pathway, producing neuroactive compounds and 
nicotinamide adenine dinucleotide (NAD
+
) (Figure 1). 
The initial and rate-limiting step in the kynurenine pathway is linked to three iron-dependent 
enzymes, indolamine 2,3-dioxygenase 1 and 2 (IDO1 and IDO2), and tryptophan 2,3-
dioxygenase (TDO). IDO was recognized in 1957 as a heme protein. The enzyme can be 
activated by interferon-γ (IFN-γ) and is present in the central nervous system (CNS), whereas 
TDO occurs primarily in peripheral tissues, especially in the liver. IDO and TDO convert Trp 
to N-formyl-L-kynurenine by opening the Trp ring in a reaction which produces peroxides 
and highly reactive oxygen and hydroxyl radicals [45-48]. N-formyl-L-kynurenine is then 
further degraded by formamidase to form L-KYN. Limited data are available about the 
biological activity of N-formyl-L-kynurenine, owing to its rapid degradation. 
L-KYN has antioxidant properties and can cross the blood-brain barrier. Some 60% of L-
KYN present in the CNS is taken up from the blood. L-KYN was demonstrated to be an 
endogenous ligand of the aryl-hydrocarbon receptor, which has important roles in the immune 
response and tumor genesis [48-52]. L-KYN can be metabolized via three different pathways. 
The first branch of the kynurenine pathway transforms L-KYN to ANA by kynureninase (L-
kynurenine hydrolase). ANA is supposed to have an anti-inflammatory effect via forming a 
complex with copper and inactivating hydroxyl radicals [53]. ANA is further metabolized to 
3-HA by 3-hydroxy-anthranilic acid 3,4-dioxygenase (3-HAO), an iron-dependent enzyme. 3-
HAO requires oxygen and sulfhydryl groups for its activation and it is predominantly present 
in astrocytes within the CNS [54, 55]. 
The second branch of the kynurenine pathway starts with the hydroxylation of L-KYN at the 
third position by the flavin-dependent kynurenine 3-monooxygenase (KMO) to yield 3-HK. 
3-HK can be further converted to xanthurenic acid (XA) and 3-HA. 3-HK and 3-HA can 
increase the level of oxidative stress via the production of free radicals, leading to neuronal 
damage [56]. Moreover, these molecules can cause excitotoxicity and cell death in neuronal 
cell cultures [57, 58]. However, ANA is also able to transform into 3-HA, which further 
transforms into QUIN (pyridine-2,3-dicarboxylic acid). QUIN is an agonist of the NMDA 
































































receptors and can cause neuronal death when administered intrastriatally [57]. It also 
provokes lipid peroxidation and generates reactive oxygen species [59]. QUIN is then 
converted to NAD
+
 in the final step of this branch of the kynurenine pathway [60]. 
The last branch of the pathway starts with the modification of L-KYN to yield KYNA (4-
hydroxi-1H-quinoline-2-carboxylic acid) by kynurenine aminotransferases (KAT)s, which 
have 4 subtypes with different biochemical profiles [61]. KATs belong to the group of 
pyridoxal 5-phosphate (PLP)-dependent enzyme family. PLP is connected covalently to the 
lysine residue of KATs by a Schiff base transaldimine link. 
KAT I (glutamine transaminase K or cysteine conjugate beta-lyase) is present in neurons and 
asytrocytes [62, 63]. KAT II (alpha-aminoadipate aminotransferase) was isolated from rat 
kidney [64]. Under physiological conditions, KATI and KAT II are proposed to be 
responsible for the majority of KYNA production in mammalians [61, 63]. 
The more recently discovered KATs include KAT III (cysteine conjugate beta-lyase 2), which 
is present in the kidney, the heart, the liver, and the neuroendocrine tissues, and KAT IV 
(glutamic-oxaloacetic transaminase 2 or mitochondrial aspartate aminotransferase). 
In contrast with QUIN, KYNA has a neuroprotective effect and can mitigate neuronal damage 
in excitotoxicity and ischemia [65, 66]. 
KYNA was discovered by Justus von Liebig in 1853 in urine, and half a century later, the 
substance was recognized as a bioproduct of Trp metabolism. KYNA is an endogenous 
metabolite of the kynurenine pathway and behaves as an antagonist at the strychnine-
insensitive glycine-binding site and, at higher doses, at the NMDA recognition site [67]. In 
addition, KYNA exerts mild antagonistic effects on kainate- and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)-sensitive glutamate receptors. Furthermore, it is of 
note that the effect of KYNA on AMPA receptor-mediated action is facilitatory at low 
concentrations (nanomolar-micromolar) and inhibitory at high concentrations (micromolar-
millimolar) [68, 69]. A line of evidence suggested that KYNA is an antagonist at the α7 
nicotinic acetylcholine receptor, thereby decreasing the presynaptic release of glutamate; 
however, this theory has recently been questioned [70, 71]. In addition, KYNA influences the 
G protein-coupled receptor 35 (GPR35) and may provoke the generation of inositol 
trisphosphate, promoting Ca
2+ 
mobilization. KYNA is present both in the central and 
peripheral tissues in low concentrations (10-150 nM), and is generated in the CNS 
predominantly by glial cells [54, 72]. 
































































Furthermore, it is worthy of note that KYNA is not the only kynurenine metabolite to have 
positive neuromodulatory effects: L-KYN, ANA, and XA can induce analgesia in the 
different types of experimental pain models [73]. 
 
Therapeutic limitations of KYNA and possible chemical solutions 
 
The main limitation of the widespread use of KYNA is its poor ability to cross the blood-
brain barrier. To overcome this problem, one possibility is to use the precursor of KYNA, L-
KYN, or its halogenated derivatives. Data from animal studies showed that L-KYN has 
neuroprotective and antinociceptive effects, and its halogenated derivatives, 4,6-
dicholorokynurenine and 4-chlorokynurenine are able to transform into halogenated KYNA 
derivatives (5,7-dichlorokynurenic acid and 7-chlorokynurenic acid, respectively), which have 
increased affinity to the glycine-binding site of NMDA receptors [33, 74, 75]. Another 
possibility is to develop KYNA analogues with improved ability to cross the blood-brain 
barrier. New KYNA analogues have a promising therapeutic potential in the treatment of 
headache as well neurodegenerative disorders [76]. Recently, our research group have created 
KYNA analogues, including(N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KA1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KA2), which successfully inhibited the trigeminal activation and 
sensitization in animal models of migraine [77, 78]. A third option is shifting the kynurenine 
pathway towards the production of KYNA by the use of specific enzyme inhibitors of 
kynureninase and KMO, the latter being the most comprehensively examined enzyme 
inhibitor of the pathway, since their inhibition prevents the production of neurotoxic 
kynurenines, such has 3-HK and QUIN. Supporting this concept, a wealth of animal data 
confirms that the inhibition of KMO is able to increase the level of KYNA and decrease that 
of 3-HK and QUIN [79, 80]. The administration of the KMO inhibitor, (R,S)-3,4-
dichlorobenzoylalanine (FCE28833A), was effective in increasing KYNA and L-KYN 
concentrations in the rat brain[81]. Representatives from another group of KMO inhibitors, N-
(4-phenylthiazol-2-yl)benzenesulfonamides, were likewise able to raise the level of KYNA in 
the extracellular hippocampal fluid [82]. 
 
Experimental data with KYNA and its analogues: preclinical and clinical implications 
 
Numerous studies indicate that KYNA and its analogues have antinociceptive effects at the 
level of both the first- and the second-order sensory neurons [83]. KYNA is capable of 
































































attenuating the activation of migraine generators and decreasing mechanical allodynia and 
pain sensitivity in the tail-flick and the hot-plate tests [84-86]. 
Systemic administration of nitroglycerin (NTG) is one of the human and animal models of 
migraine, resulting in the activation and sensitization of the trigeminal system. Pretreatment 
with L-KYN together with probenecid (PROB; an inhibitor of KYNA excretion) or that with 
KYNA analogues, KA1 or KA2, attenuated the NTG-induced behavioral changes in the rat as 
well as morphological alterations in the TNC, probably by the inhibition of NMDA receptors 
[32, 33, 78]. In a recent study, it has been shown that NTG decreased the expression of KAT 
II, an enzyme converting L-KYN to KYNA, probably implicating decreased KYNA levels as 
well[87]. 
Another experimental setting takes advantage of the electrical stimulation of the TRIG, which 
also results in decreased KAT immunoreactivity in mast cells, Schwann cells, and dural 
macrophages [88]. 
Several studies have shown that there is a connection between the kynurenines and the CSD. 
CSD is a self-propagating process, the electrophysiological correlate of migraine aura, and is 
able to activate the trigeminal system in experimental animals [89, 90]. L-KYN and KYNA 
suppressed CSD in a KCl-induced model [34, 35]. 
Another model of the trigeminal activation and sensitization takes advantage of the Complete 
Freund’s Adjuvant (CFA)-induced dural inflammation. In this model, a KYNA analogue was 
able to abolish the CFA-generated inflammatory response [91]. 
To examine trigeminal inflammation and nociception, the orofacial formalin test can also be 
used, as a stable model for the investigation of somatic pain involving the activation and 
sensitization of the trigeminal system [92]. In this model, PROB exerted an antinociceptive 
effect in rats [93]. Notably, PROB is able to increase the concentration of KYNA by 
inhibiting its excretion in the nervous system, which may contribute to the observed 
antinociceptive effect [94]. In a most recent study, the effects of two KYNA analogues, KA1 
and KA2, were tested in the orofacial formalin model, revealing that the two analogues were 
able to inhibit the formalin-induced behavioral and morphological changes and increased the 
concentration of KYNA [95]. 
 
Although the exact mechanism of action of KYNA and its analogues remains unknown, some 
pieces of the puzzle are starting to fall into place. KYNA can exert its effect both in the 
periphery and in the CNS. In the periphery, KYNA acts on the glutamate receptors, especially 
NMDA receptors, localized on certain components of the peripheral nervous system, 
































































including the trigeminal and dorsal root ganglion, Schwann cells, and the primary sensory 
afferents [96-99]. As mentioned above, KYNA also has an effect on the GPR35 receptor, 
which is present in the nociceptive pathway, for example in the dorsal root ganglion; therefore, 
KYNA may exert its peripheral effect in part on this receptor [100]. 
In addition to a peripheral action, KYNA and its analogues have a modulatory potential on 
second-order neurons as well. KYNA was effective in providing analgesia in the tail-flick, 
hot-plate, and orofacial formalin tests in mice and rats, as mentioned above. These results are 
in line with animal studies reporting that kynurenine metabolites can influence pain sensation 
at the level of the spinal cord [84]. When administered into the spinal cord of cats, KYNA 
was effective in decreasing the muscular and cutaneous nociceptive reaction of wide dynamic 
range neurons [101]. In rats, KYNA and its analogues were able to prevent the NTG- or CFA-
induced activation and sensitization of the trigeminal system in the TNC, where the trigeminal 
second-order nociceptive neurons are located [32, 33, 78, 91]. Therefore, KYNA and its 
derivatives can influence the second-order neurons in the trigeminal system. 
There is a number of experimental data suggesting that kynurenines influence the activity of 
migraine generators, including the NRM, the DRN, the LC, and the PAG. Indeed, KYNA can 
decrease serotonergic responses of the DRN induced by phasic auditory stimulation or the 
electrical stimulation of the lateral habenula [102, 103]. KYNA can also diminish the 
activation of the NRM neurons induced by glutamate, and is able to prevent the activation of 
noradrenergic neurons in the LC provoked by electrical stimulation of the hindpaw of rats 
[104, 105]. In addition, the co-administration of KYNA with morphine into the PAG 
increased the nociceptive effect of morphine [106]. 
To date, only few clinical data are available as regards kynurenine pathway alterations in 
migraine. Recent studies by Curto and her colleagues showed altered serum levels of 
kynurenine metabolites (L-KYN, KYNA) in patients with chronic migraine and cluster 
headache [36, 107]. This group was the first to conclude that these two types of primary 
headaches are both associated with decreased levels of kynurenine metabolites in the 
peripheral blood. 
Summarizing the preclinical and clinical data from the literature, we can conclude that the 
metabolites of the kynurenine pathway appear to play relevant roles in the pathomechanism of 
migraine, and they might represent a new potential therapeutic option in the treatment of the 
disease (Figure 2). 
 
 
































































Link between the kynurenines and the other endogenous systems 
 
Several lines of evidence have been put forth to support the hypothesis that the kynurenine 
pathway has a strong interaction with other endogenous systems, including the 
endocannabinoid system. Recently, numerous studies have indicated that changes in the levels 
of endocannabinoids within the nervous system are associated with nociception and the 
pathomechanism of migraine [108]. An increased level of KYNA achieved by the use of the 
KMO inhibitor 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide (also 
known as Ro 61-8048) was capable of reducing the self-administration of ∆
9
-
tetrahydrocannabinol (THC) in squirrel monkeys [109]. In addition, the first discovered 
endocannabinoid, anandamide, was able to attenuate the NTG-induced decrease in KAT II 
expression [87]. 
Another endogenous system influenced by KYNA is the opioid system. The co-administration 
of KYNA with morphine raised the acute effect of morphine in rats [106]. Furthermore, 
KYNA and KA1 reduced the opioid and nociceptin receptor-mediated G-protein activity 
without demonstrating any affinity towards of opioid receptors [106, 110], an indirect effect 
which can be attributed to a decreased G-protein activity or a diminished expression of opioid 
receptors [110]. 
On the other hand, KYNA plays an important role in the regulation of dopaminergic 
neurotransmission. An increase in the level of KYNA results in the inhibition of dopamine 
release; therefore, KYNA is able to influence the levels of dopamine [111]. The decreased 
level of brain KYNA as a result of the inhibition of KAT II was able to cause an elevation in 
the extracellular levels of dopamine [112]. In addition, alterations in brain KYNA 
concentration can be associated with cognitive effects. Indeed, administration of KYNA or L-
KYN to rats caused impairments in visuospatial working memory, sensory gating, and 
contextual learning, phenomena linked to glutamatergic and dopaminergic neurotransmission 
[113-115]. 
It is also important to note that TDO activity is under the control of blood corticosterone 
levels and the activity of IDO is regulated by steroids [116, 117]. 
The immune system represents another endogenous system which has a strong connection 
with kynurenines. IDO has essential roles in immune modulation in relation to processes such 
as infection, transplantation, autoimmunity, and pregnancy. IDO is an immunosuppressive 
enzyme, with a number of its products being able to inhibit T cell proliferation and activate 
regulatory T cells; therefore, IDO might have an effect on the negative feedback suppression 
































































of T cell response [118]. Importantly, a chronic CNS inflammation might cause an increased 
activity of IDO by an IFN-γ-mediated process, a phenomenon which might contribute to the 
pathomechanism of migraine [18]. Notably, not only kynurenines can influence the immune 
system, but immune molecules such as cytokines can in turn modulate the activity of the 
kynurenine pathway as well: in particular, tumor necrosis factor-α (TNF- α) and interleukins 
(IL)s, IL-1, -2, -4, -13, and -23 have a strong modulatory effect on the activation of IDO [118]. 
 
Influencing the kynurenine pathway – chemical and nutritional aspects 
 
Several enzymes of the kynurenine pathway are vitamin-dependent, including KMO, 
kynureninase, and the KATs [119]. A number of vitamins from the B family can either 
directly or indirectly upregulate and/or downregulate the activity of the above mentioned 
enzymes. In particular, vitamin B6 (pyridoxal) has a crucial role in Trp metabolism, being 
implicated in the physiological function of both the serotonin and kynurenine pathways, and it 
also functions as a coenzyme of the KATs and kynureninase [120]. These data are in 
accordance with a recent study demonstrating that the combined application of vitamin B6 
and B12 was effective in the reduction of migraine-associated symptoms [121]. 











[120]. Metal ions can 
also catalyze non-enzymatic reactions of amino acids with pyridoxal, influencing the function 
of PLP enzymes [122, 123]. As the polar side chain of proteins could interact with metal ions, 









 can inhibit the 
activity of both the KATs and kynureninase by the blockage and inactivation of sulfhydryl 
groups of the enzymes [124, 125]. These results raise the interesting possibility that 
influencing the enzymes of the kynurenine pathway by vitamin B6 or cations might have a 
therapeutic potential. 
Recently, a growing attention has been dedicated to the nutritional aspects of kynurenines. 
Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenol, which can be found in several 
nutrients, including red wine, peanuts, and cocoa. It has immunomodulatory and anticancer 
effects [126, 127]. A recent study has shown that resveratrol intake enhanced the activity of 
IDO in human volunteers [128]. Though in this study, no significant change was observed in 
the levels of L-KYN, the possibility cannot be excluded that resveratrol can influence the 
levels of kynurenine metabolites. Furthermore, one should keep in mind that several types of 
































































red wine are able to induce migraine attacks. The contribution of the non-flavonoid 
resveratrol in wine-triggered attacks is suggested to be unlikely, and tannins and phenolic 
flavonoid components of the wine are generally considered to be responsible for the induction 
of migraine attacks [129]. 
 
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 
 
Basic biochemical features of PACAP and its receptors 
 
PACAP is a member of the VIP/secretin/glucagon neuropeptide superfamily and is considered 
to be a ‘brain-gut peptide’, being widely expressed in the animal and human organisms [37, 
130]. PACAP was discovered based on its ability to increase adenylate cyclase activity in rat 
pituitary cells, and was first isolated from the ovine hypothalamus in 1989 [131]. Genetic 
studies showed that the human gene of PACAP (ADCYAP1) is localized on the short arm of 
chromosome 18 (18p11) [132]. The chemical structure of the peptide exists in two 
biologically active amidated forms, referred to as PACAP1-38 and PACAP1-27, containing 
38 and 27 amino acids, respectively (Figure 3). PACAP1-38has been revealed to account for 
some 90% of the total PACAP content in mammalian tissues; however, it is rapidly 
metabolized and its plasma elimination half-life is very short, being less than 5 min [133]. 
PACAP can be found in the central and peripheral nervous systems, in the endocrine and 
exocrine glands, e.g., pancreas and gonads, as well as in the urogenital and respiratory 
systems, thereby it functions as a pleiotropic peptide [134-142]. PACAP has many functions 
asa hypophysiotropic hormone; furthermore, it also works as a neuromodulator and 
neurotransmitter within the nervous system [143-147] 
In addition, PACAP exerts antiapoptotic, neuroprotective, and differentiation-inducing effects 
in the developing nervous system [143-148]. In addition, it plays crucial modulatory and 
protective roles in the reproductive, cardiovascular, gastrointestinal, and respiratory systems 
[149-155]. 
The actions of PACAP are mediated via the following three receptors: VPAC1 (formerly 
designated the VIP, VIP1 or PACAP type II receptor), VPAC2 (known as the VIP2 or 
PACAP type III receptor), and PAC1 (previously referred to as the PACAP type I receptor). 
The PAC1 receptor has a 1000-fold higher affinity for PACAP1-27 and PACAP1-38 than for 
VIP [156-158]. The effect of PACAP on its different receptors induces two substantial signal 
transduction pathways. Through Gs- or Gq/11-protein activation, a number of kinases exert a 
































































variety of physiological and pathophysiological effects [37, 156]. It has been demonstrated 
that PACAP1-38-induced meningeal vasodilation is realized by the activation of VPAC2 
receptors [159]. The investigation of the TS as regards PACAP and the release of 
calcitonin gene-related peptide (CGRP), a molecule relevant in the pathogenesis of 
migraine[14], demonstrated that unlike PACAP1-38, maxadilan, a PAC1 receptor 
agonist, had no effect on CGRP release in the TNC, whereasM65, a PAC1 receptor 
antagonist, failed to inhibit the PACAP 1-38-induced release of CGRP. These together 
raised the possibility of the functional presence of a yet unidentified receptor of PACAP 
in the TS [160]. Another experimental study reported that only intracerebroventricular 
administration of a PAC1 receptor antagonist was able to diminish the activation of the 
second-order nociceptive neurons in the trigemino-cervical complex during dural 
stimulation [161]. 
The functions of PACAP in nociceptive and vasodilation processes have been revealed by 
many studies [162-170]. Immunohistochemical studies demonstrated the presence of this 
peptide in the trigeminal system, e.g., TRIG, TNC, and different brainstem nuclei [38, 39, 
134, 171, 172]. Immunohistochemical data demonstrated the presence of PAC1 and 
VPAC2 receptors in small-diameter TRIG neurons [173]. Reverse transcription-
polymerase chain reaction revealed the presence of VPAC2 and several splice variants of 
the PAC1 receptor in TRIG [173]. There is functional evidence that VPAC1 receptors 
are lacking in the TRIG of rats [174] (Figure 4). An early study showed that about 68% of 
nociceptin-immunopositive cells in the human TRIG contained PACAP [175]. A human 
tissue study examining the TNC and the cervical 1–cervical 2 (C1–C2) levels of the spinal 
cord concluded that the moderately dense CGRP- and PACAP-containing fibers can be 
detected in the vicinity of numerous substance P (SP)-immunoreactive fibers, but VIP-
immunoreactive fibers were not observed [134]. Moreover, PACAP was detected in human 
parasympathetic otic and sphenopalatine ganglia [176-178]. PACAP1-38 immunoreactivity 
was found in neurons and satellite glia cells in rat sphenopalatine ganglia [178]. A broad 
range of data suggests that PACAP functions as an integrator of nociceptive and sensitization 
processes, besides being involved in neurogenic inflammation [164, 166, 170, 179]. PACAP 
and glutamate were both detected in the TRIG of rhesus monkeys and rats [180]. 
 
Link between PACAP and migraine 
 
































































The exact pathomechanism of migraine is unknown, but the activation and sensitization of the 
TS are among the leading hypotheses [13, 14]. There is a number of evidence highlighting the 
possible role of PACAP in the pathogenesis of migraine. The first human evidence that 
demonstrated the significance of PACAP in migraine was published by Schytz et al. in 2009 
[40]. Intravenous infusion of PACAP1-38 caused delayed migraine-like attacks, similarly to 
the effect of nitroglycerin infusion in migraineurs [40, 181, 182]. Moreover, the decrease of 
the mean blood flow velocity in the middle cerebral artery and the increase of the diameter of 
the superficial temporal artery were also observed in the PACAP study of migraineurs [40]. 
After these promising clinical data, preclinical animal studies were performed to explain the 
background of the effect of PACAP in the human body [42, 43]. After chemical (by 
nitroglycerin) and electrical (at the TRIG) stimulation of TS, PACAP1-27 and PACAP1-
38immunoreactivity were found significantly increased in TNC in rats. Even more, PACAP1-
38 elevation was found in the plasma after the electrical stimulation of the TRIG in rats [42]. 
PACAP-deficient mice displayed reduced light-aversive behavior (photophobia), and 
decreased meningeal blood flow and c-fos expression were detected in the TRIG and TNC 
relative to wild-type mice after nitroglycerin-induced TS activation [43]. Neurogenic 
inflammation and mast cell degranulation also take part in the process of migraine [183, 184]. 
After mast cell degranulation, the released histamine may induce a long-lasting activation of 
the TS. It has been demonstrated that vasodilation induced by systemically administered 
PACAP1-38 was diminished in mastocyte-depleted and antihistamine-pretreated rats [185]. 
PACAP has the capability to release histamine from rat peritoneal or human skin mast cells 
[186, 187]. VPAC1 receptor is expressed on mast cells [188]. The importance of mast cell 
degranulation within the dura is given by its possible association with the activation of 
peripheral trigeminal fibers, which leads to peripheral sensitization [184, 189, 190]. 
Electrophysiological studies proved that PACAP1-38 could cause delayed activation and 
sensitization of second-order neurons in the trigemino-cervical complex, in a process 
mediated by neuronal PAC1 receptor in rats [161]. Magnetic resonance angiography of 
selective extra- and intracranial arteries in humans revealed marked and long-lasting dilation 
of extracranial arteries after PACAP1-38 infusion [41]. Elevated plasma PACAP1-38 
immunoreactivity was detected in the spontaneous ictal period compared to the interictal 
phase of migraineurs [44]. Interestingly, similar data were found in episodic cluster headache 
patients [191]. However, in tension-type headache patients, interictal plasma PACAP level 
was unchanged, whereas in the same phase, it was found decreased in migraineurs [192]. A 
recent clinical study revealed that PACAP mRNA expression in the peripheral blood 
































































mononuclear cells in migraine patients was significantly reduced compared to tension-type 
headache, cluster headache, or medication overuse headache patient groups [193]. During the 
ictal period, PACAP plasma level in the external jugular vein was found elevated, which 
alteration was reduced 1 hour after treatment with sumatriptan, a potent acute anti migraine 
drug [194]. In a clinical study, previously genotyped patients with migraine without aura were 
infused by PACAP1-38, which resulted in delayed migraine-like attacks and elevated plasma 
levels of VIP, prolactin, S100 calcium binding protein B, and thyroid-stimulating hormone 
[195]. This finding pointed out that PACAP may activate parasympathetic nerve endings, 
causing VIP release [195]. However, the presence of the MEF2D gene variant (rs2274316) 
was not associated with pre-ictal alterations in neuropeptide levels in the plasma, and neither a 
high family load nor the presence of this risk allele influenced the migraine response to 
PACAP1-38 infusion [195, 196]. A resting-state functional MRI study demonstrated that 
intravenously administered PACAP1-38-induced migraine attacks are associated with altered 





Theoretically, PACAP may be released from the peripheral and central terminals of the 
trigeminal nerve endings. Peripherally released PACAP may cause vasodilation and mast cell 
degranulation, resulting in peripheral sensitization. On the other hand, centrally released 
PACAP may lead to the activation of second-order sensory neurons in the TNC in a process 
mediated by the PAC1 receptor, which leads to central sensitization. Both the peripheral and 
the central sensitization processes take part in the initiation of migraine attacks [19, 184, 198-
201]. 
 
A possible link between PACAP and kynurenines in pathogenesis of migraine 
 
The glutamatergic system represents a possible link between PACAP and kynurenine 
pathway as regards the pathomechanism of migraine. Electrophysiological and 
biochemical clinical studies revealed the presence of cortical hyperexcitability in 
migraine patients, which pointed to the role of the glutamatergic system in 
pathomechanism of migraine [20, 202-205]. Experimental data exist suggesting the role 
of PACAP on the glutamatergic system via its receptors. It has been proposed that 
































































PACAP may promote the functional coupling between neuronal nitric oxide synthase 
and NMDA receptors in inflammatory pain processes [179]. Furthermore, a study using 
the contextual fear conditioning animal model demonstrated that PACAP modulated the 
consolidation and extinction through NMDA receptors [206]. In the ventromedial nuclei 
of the hypothalamus, PACAP modulated the NMDA receptor activity via tyrosine 
phosphorylation by the Src kinase family [207]. In addition to actions on NMDA 
receptors, PACAP1-38 was shown to regulate the phosphorylation of AMPA receptor in 
hippocampal cultures [208]. On the basis of the distribution of PACAP and glutamate in 
the TRIG, immunohistochemical data suggests a possible interaction between the 
glutamatergic and the CGRP systems [180]. 
Migraine-related peripheral and central sensitization of the TS is guided by the 
glutamatergic system, which can be influenced by kynurenines and PACAP. Recent 
clinical trials in migraine have investigated ionotropic NMDA receptor antagonists (e.g., 
ketamine and memantine) [209, 210], an ionotropic AMPA receptor antagonists (e.g., 
BGG492, a.k.a. selurampanel) [211], an ionotropic AMPA/kainate receptor antagonists 
(LY293558, a.k.a. tezampanel) [212], and a metabotropic glutamate receptor 5 
modulator (ADX-10059, a.k.a. raseglurant) [213]. Glutamatergic receptors may serve as 




Migraine is a neurovascular disorder with an unknown etiopathogenetic background. 
One of the leading hypotheses is based on the activation and sensitization of the TS. 
Distinct members of kynurenine system, such as L-KYN and KYNA, as well as the 
recent hypothetical migraine-related neuropeptide, PACAP, may be connected by their 
influence on the glutamatergic elements of TS. The activation of excitatory 
glutamatergic receptors leads to the sensitization of TS. KYNA and its analogues are 
antagonists of the glutamatergic receptors. PACAP modulates the NMDA and AMPA 
receptors. Moreover, PACAP exerts its effects on the TS through its receptors (VPAC1, 
VPAC2, and PAC1). 
As regards future perspectives, KYNA analogues, PAC1 receptor antagonists, and 
glutamatergic receptor antagonists may provide innovative therapeutic options in 
migraine headache. 
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Figure 1. A part of the kynurenine pathway 
 



































































Figure 2. The main action of kynurenic acid and quinolinic acid. 














































































































































































Figure 4. Localization of PACAP and its receptors in the trigeminovascular system 
Abbreviations: NRM: nucleus raphe magnus; LC: locus coeruleus; VPAC1: previously 
designated as the VIP, VIP1 or PACAP type II receptor, VPAC2: known as the VIP2 or 
PACAP type III receptor; PAC1: formerly known as the PACAP type I receptor; PACAP: 
pituitary adenylate cyclase-activating polypeptide; PAG: periaqueductal grey matter; TNC: 
trigeminal nucleus caudalis; TRIG: trigeminal ganglion [173, 174, 184] 
DURA MATER      PACAP, PAC1, VPAC1, VPAC2 
CORTEX          PACAP, PAC1, VPAC1, VPAC2 
PAG          PACAP, PAC1 
PACAP, PAC1        LC 
PACAP, PAC1       NRM 
TNC         PACAP, PAC1, VPAC1 









































































Figure 1. A part of the kynurenine pathway. 
 
Figure 2. KYNA and its analogues are able to inhibit the glutamate-induced hyperexcitability, 
which has a relevant role in the pathomechanism of migraine. 
 
Figure 3.Amino acid sequences of PACAP-27 and PACAP-38. 
 
Figure 4. PACAP and its receptors are expressed in various parts of the trigeminovascular 
system. 
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KYNA and its analogues are able to inhibit the glutamate-induced hyperexcitability, which has a relevant role 
in the pathomechanism of migraine.  
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DURA MATER PACAP, PAC1, VPAC1, VPAC2
PAG PACAP, PAC1
PACAP, PAC1                        LC
PACAP, PAC1                   NRM
TNC PACAP, PAC1, VPAC1
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